Ensemble Therapeutics Corporation Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today that the company has identified a series of unique small molecule antagonists of Interleukin-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s and intestinal bowel disease. The Ensemblins represent first-in-class small molecule antagonists of this important, clinically validated protein-protein-interaction target that has proven impervious to traditional small molecule pharmaceutical approaches and has only been addressed to date with protein therapeutics. A small orally active inhibitor of IL-17 would have significant advantages over the current class of clinical stage anti-IL-17 antibody products.